Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
Prif Awduron: | Plata-Munoz, J, Vaidya, A, Fuggle, S, Friend, P |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
2009
|
Eitemau Tebyg
-
Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
gan: Haynes, R, et al.
Cyhoeddwyd: (2014) -
Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
gan: Haynes, R, et al.
Cyhoeddwyd: (2014) -
Impact of monoclonal antibody based-induction therapy on postoperative graft function and survival of kidneys from non-heart-beating donors.
gan: Plata-Munoz, J, et al.
Cyhoeddwyd: (2007) -
The deceased donor score system in kidney transplants from deceased donors after cardiac death.
gan: Plata-Munoz, J, et al.
Cyhoeddwyd: (2010) -
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
gan: Haynes, R, et al.
Cyhoeddwyd: (2014)